Mylan (MYL) Gains Early After Taking Action on EpiPen Pricing
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
After dropping sharply over the past few sessions on headline risk related to EpiPen pricing, Mylan (NASDAQ: MYL) shares are gaining 3% early after the company announced plans to reduce patient cost through savings card which will cover up to $300 for their EpiPen 2-Pak.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mylan's Commitment to Stemming the Tide of HIV/AIDS as Strong as Ever
- Proshares Trust Ultrashort Lehman 20+ Year Treasury (TBT)
- Under Armour (NYSE: UA) volatility low as shares trade near 52-week low